...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annual Review of Pharmacology and Toxicology >DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility
【24h】

DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility

机译：Dreadds（专门由设计者药物激活的设计者受体）：具有治疗效用的化学工具

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the past decade, emerging synthetic biology technologies such as chemogenetics have dramatically transformed how pharmacologists and systems biologists deconstruct the involvement of G protein-coupled receptors (GPCRs) in a myriad of physiological and translational settings. Here we highlight a specific chemogenetic application that extends the utility of the concept of RASSLs (receptors activated solely by synthetic ligands): We have dubbed it DREADDs (designer receptors exclusively activated by designer drugs). As we show in this review, DREADDs are now used ubiquitously to modulate GPCR activity noninvasively in vivo. Results from these studies have directly implicated GPCR signaling in a large number of therapeutically relevant contexts. We also highlight recent applications of DREADD technology that have illuminated GPCR signaling processes that control pathways relevant to the treatment of eating disorders, obesity, and obesity-associated metabolic abnormalities. Additionally, we provide an overview of the potential utility of chemogenetic technologies for transformative therapeutics.
机译：在过去的十年中，诸如化学物质的新兴的合成生物学技术大大转化了药剂学家和系统生物学家如何在无数的生理和翻译环境中解构G蛋白偶联受体（GPCR）的累积。在这里，我们突出了一种特定的化学基因应用，其延伸了RASSLs概念的效用（仅通过合成配体激活的受体）：我们被称为DREADDS（专门由设计者药物激活的设计者受体）。正如我们在本次审查所展示的那样，DREADDS现在普遍使用以在体内不禁止地调节GPCR活动。这些研究的结果直接将GPCR信号直接涉及大量治疗相关的背景。我们还突出了近期具有照明GPCR信号传导过程的Dreadd技术的应用，该过程可控制与饮食障碍，肥胖症和肥胖相关的代谢异常相关的控制途径。此外，我们还概述了转化性治疗的化学技术的潜在效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号